SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest strong topline results from its Phase 3 RASolute 302 clinical trial, triggering significant price appreciation and active discussion regarding the company's future as a potential buyout target. Community sentiment remains highly bullish, with many highlighting the stock's robust cash position and the transformative potential of its daraxonrasib treatment for pancreatic cancer.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending due to the resignation of its top lawyer amid revelations of ongoing ties to Jeffrey Epstein, triggering a sharp decline in share price. Investors are also closely monitoring the bank's exposure to volatile credit markets and broader concerns regarding institutional stability during a period of geopolitical uncertainty.

Maulcoin

Maulcoin is capturing attention as a community-driven meme project that is consistently trending on social platforms without an official chart, fueling intense community speculation about an upcoming breakout. Holders are actively discussing milestone targets for market capitalization and expressing strong commitment to the project's long-term growth and cultural branding.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors weigh its potential for massive growth in silicon photonics against the execution risks associated with its transition from early-stage government contracts to commercial-scale manufacturing. Community sentiment is sharply divided between those bullish on its proprietary 300mm wafer technology as a high-reward play and those skeptical of its current revenue levels and recurring share offerings.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant market interest driven by a combination of high trading volume, a short squeeze, and momentum following its expansion and integration with the USD1-denominated ecosystem. While some community members are actively debating the token's long-term utility and governance, others are focused on its rapid price action and speculative potential as a trending Web3 entertainment protocol.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging following positive Phase 2/3 trial results for its metastatic uveal melanoma treatment, which significantly improved progression-free survival compared to standard therapies. Investors and the community are actively debating the potential for an accelerated FDA filing, while also closely watching for future pipeline updates and high institutional interest.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Aeglea BioTherapeutics Inc

Spyre Therapeutics is seeing significant investor interest following positive clinical data for its SPY001 program, with the community actively discussing the company's multi-pathway platform approach and its potential to disrupt the IBD market. While some investors are focused on the long-term potential of its upcoming pipeline milestones, others remain cautious regarding the risks typically associated with clinical-stage biotechnology companies.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a volatile spotlight following a combination of a high-profile endorsement from Donald Trump and intense short-selling pressure from investors like Michael Burry. The community remains deeply divided, with bulls pointing to the company's critical role in military AI and defense contracts, while bears raise significant concerns regarding its current valuation and rising competition from alternative AI models.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and heightened scrutiny as traders debate whether current valuation levels represent a sustainable AI-driven growth cycle or an overheated bubble. The community is actively tracking a sharp divergence between high-flying hardware momentum and a struggling software sector, while aggressive options activity and short-dated put sweeps suggest that institutional players are bracing for significant downside risks.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is facing intense community debate as investors weigh concerns over potential dilution and future stock splits against optimism surrounding the commercial traction and insurance coverage expansion of their lead product, Tonmya. While some shareholders are selling amid downward price pressure and a history of capital raises, others are aggressively buying the dip, citing strong long-term pipeline fundamentals and recent insider share purchases as evidence of an impending turnaround.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

INDP, PATH, TRIB, SOC, MCD were among the stocks seen among investors on Tuesday, Dec. 23, 2025.read more...

<ul class="summary-bullets"><li>Trinity Biotech’s shares were up nearly 47% in Tuesday’s midday trade after the company announced that it had secured an order for nine million units of its TrinScreen HIV rapid diagnostic test.</li><li>Starfighters Space shares were down over 51% in Tuesday’s midday session, taking a breather after a massive 371% rally on Monday.</li><li>VisionWave shares were up nearly 8% in Tuesday’s midday trade after the company announced the issuance of a new patent that covers the systems and methods for real-time movement, position detection, and imaging technology.</li></ul>U.S. equities traded in the green on Tuesday noon amid optimism about a Santa Claus rally, with the Dow Jones Industrial Average, S&amp;P 500, and the Nasdaq Composite on course for their fourth consecutive winning session.Earlier in the day, the Bureau of Economic Analysis&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-q3-december-2025/cLep8gzREuU">reported</a> that the U.S. economy grew at an annualized rate of 4.3%, higher than the Dow Jones forecast of 3.2%, as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-q3-december-2025/cLep8gzREuU">cited</a> by MarketWatch.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.28% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, gained 0.25%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, rose 0.18%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Tuesday’s midday trade:</h2><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk AS (NVO)</a>Novo Nordisk shares were up more than 9% in Tuesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-stock-soars-after-hours-as-fda-greenlights-wegovy-pill-for-weightloss/cLeFw1kREu2">said</a> that its Wegovy pill for weight loss has been approved by the U.S. Food and Drug Administration (FDA), making it the first oral GLP-1 class drug for weight management approved by the agency.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 39% year-to-date.<a href="https://stocktwits.com/symbol/TRIB">Trinity Biotech Plc. (TRIB)</a>Trinity Biotech’s shares were up nearly 47% in Tuesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-trinity-biotech-stock-surge-nearly-50-in-premarket-today/cLepnI7REuv">announced</a> that it had secured an order for nine million units of its TrinScreen HIV rapid diagnostic test, scheduled for delivery in the fourth quarter (Q4) of 2025 and the first quarter (Q1) of 2026.<a href="https://stocktwits.com/symbol/TRIB">TRIB stock</a> is up 48% year-to-date.<a href="https://stocktwits.com/symbol/FJET">Starfighters Space Inc. (FJET)</a>Starfighters Space shares were&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fjet-stock-takes-a-breather-post-massive-rally/cLepsN8REH7">down</a> over 51% in Tuesday’s midday session, taking a breather after a massive 371% rally on Monday. The company laid out its 2026 plans, stating that the convergence of government demand, growth in the commercial space segment, and public market access following its IPO positions it well.<a href="https://stocktwits.com/symbol/FJET">FJET stock</a> is up 56% year-to-date.<a href="https://stocktwits.com/symbol/VWAV">VisionWave Holdings Inc. (VWAV)</a>VisionWave shares were up nearly 8% in Tuesday’s midday trade after the company announced the issuance of a new patent that covers the systems and methods for real-time movement, position detection, and imaging technology.<a href="https://stocktwits.com/symbol/VWAV">VWAV stock</a> is up 263% year-to-date.<a href="https://stocktwits.com/symbol/NOW">ServiceNow Inc. (NOW)</a>ServiceNow shares were down nearly 3% in Tuesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/service-now-acquires-armis-in-7-75-billion-deal-to-strengthen-ai-powered-security-platform/cLepYSLREHb">announced</a> the acquisition of cybersecurity startup Armis in a $7.75 billion deal as it looks to bolster its offerings amid rising threats due to the expanding use of AI.<a href="https://stocktwits.com/symbol/NOW">NOW stock</a> is down 28% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fjet-stock-takes-a-breather-post-massive-rally/cLepsN8REH7">FJET Stock Takes A Breather Post Massive Rally – Starfighters Space Releases 2026 Plans After Stock Market Debut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Novo Nordisk, Trinity Biotech, Starfighters Space, VisionWave, ServiceNow: Stocks Making The Biggest Moves Today

Novo Nordisk shares were up more than 9% in Tuesday’s midday session after the company said that the U.S. FDA has approved its Wegovy pill for weight loss.

Equity

<ul class="summary-bullets"><li>Trinity posted a 32% sequential increase in third-quarter revenue to $14.3 million, driven by a $2.1 million increase in rapid HIV test sales.</li><li>The company entered into new financing agreements with funds managed by Perceptive Advisors.</li><li>The deal includes $5 million in new term-loan funding and up to $60 million in elective equitization capacity.</li></ul>Trinity Biotech (TRIB) shares surged nearly 50% in premarket trading on Tuesday, after the company said it had secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.The WHO-prequalified rapid diagnostic test is designed for high-volume screening programs and will be produced through the company’s recently approved outsourced manufacturing process. Trinity Biotech expects to fulfil the order across the fourth quarter of 2025 and the first quarter of 2026, with the contract set to support revenue growth.<a href="https://stocktwits.com/symbol/TRIB">Trinity Biotech</a> also posted a 32% sequential increase in third-quarter revenue to $14.3 million, driven by a $2.1 million increase in rapid HIV test sales, while adjusted EBITDA improved to a $0.5 million profit from a $2.1 million loss in Q2.The company said it continues to advance its transformation plan after securing key regulatory approvals, including WHO authorization to outsource production of its Uni-Gold HIV rapid test. These milestones are expected to drive efficiency gains and support rising adjusted EBITDA through the first half of 2026."Our operating and financial improvement in Q3 2025 was encouraging, in particular the achievement of positive Adjusted EBITDA. This gives us confidence that our Comprehensive Transformation Plan is on track and, when combined with our exciting innovation agenda, leaves the business well positioned for further progress in 2026,” said John Gillard, CEO of Trinity Biotech. &nbsp;<h2 class="st-heading-2">Trinity's Financing Plans</h2>Trinity Biotech also entered into new financing agreements with funds managed by Perceptive Advisors to strengthen liquidity and improve capital structure flexibility.&nbsp;The deal includes $5 million in new term-loan funding and up to $60 million in elective equitization capacity, which could lower debt and interest costs. The agreements also introduce equity-based settlement options for certain obligations, supporting Trinity Biotech’s long-term growth and investment plans.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to 'extremely bullish' from 'extremely bearish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/TRIB_png_e777e3d7ee.webp" alt="TRIB.png">One user sees $1.75 as a key resistance point.<stembedurl>https://stocktwits.com/TeamBullish/message/639966430</stembedurl>Year-to-date, the stock has gained 43%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Trinity Biotech Stock Surge Nearly 50% In Premarket Today?

Trinity Biotech (TRIB) shares surged nearly 50% in premarket trading on Tuesday, after the company said it had secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.

The company secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.

Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

Trinity Biotech&nbsp;notched its best session on record on Thursday after its New York reference laboratory received approval from the New York State Department of Health to begin offering the FDA-cleared PreClara Ratio biomarker test for assessing the risk of preeclampsia.&nbsp;Shares of Trinity Biotech soared 89.1% to $1.9 on Thursday, marking its best session since the company’s launch in 1992, before sliding 16% to $1.6 in after-hours trading. Additionally, trading volume in Trinity surged to 208.5 million shares on Thursday, more than 1,160 times its average daily volume of 178,948.The service, which has a planned release in the third quarter (Q3) of 2025, is expected to support clinicians in making more rapid and informed decisions for patients hospitalized with hypertensive disorders of pregnancy, a complex set of conditions that impacts approximately 500,000 women annually in the U.S.&nbsp;The test, by estimating the risk of progression to severe preeclampsia, can enable earlier and more precise interventions.&nbsp;Research published in March estimated the potential to achieve more than $10 million in neonatal cost savings per 1,000 patients with the test as part of standard care, largely due to a reduction in preterm births and NICU days.The approval also paves the way for Trinity's expected launch of PrePsia, its proprietary technology that screens for preeclampsia risk earlier in pregnancy.&nbsp;Preeclampsia is estimated to affect 5–8% of pregnancies. The condition is a major driver of maternal and neonatal complications in the U.S., accounting for approximately 11% of maternal deaths and 15% of premature births.The PreClara Ratio is designed for use alongside other laboratory tests and clinical assessments in women between 23 and nearly 35 weeks of pregnancy who are hospitalized with hypertensive disorders.&nbsp;It calculates a ratio from specific blood test results to estimate the short-term risk of developing severe preeclampsia.On Stocktwits, retail sentiment for Trinity Biotech was ‘extremely bullish’ amid a 7,211% surge in 24-hour message volume.One user remarked that they expected Trinity Biotech to climb back over $3.00 the next day, urging others to “buy the dips and hold,” adding that all short shares were accounted for and the stock “can rip and halt like it did today.”&nbsp;<stembedurl>https://stocktwits.com/Magicians/message/625281470</stembedurl>Another user speculated that the sharp rise could be followed by a dilution announcement, noting the stock was now “going down on huge volume.”&nbsp;<stembedurl>https://stocktwits.com/Huskersnsaints/message/625247540</stembedurl>A third user predicted it could “easily break $4.00” going into the next session, recommending buying at market price and holding.<stembedurl>https://stocktwits.com/Magicians/message/625225289</stembedurl>Trinity Biotech’s stock has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Trinity Biotech (TRIB) soared 89.1% to $1.9 on Thursday, marking its best session since the company’s launch in 1992. (Photo credit: Getty Images)

Trinity Biotech Stock Marks Best Day Ever On New York Greenlight For Pregnancy Risk Test; Retail Sees More Upside

Trading volume in Trinity Biotech spiked to more than 1,160 times its daily average after regulators cleared the PreClara Ratio test, which helps doctors identify pregnant patients at risk of developing severe preeclampsia.

Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for positive reasons.Trinity Biotech (<a href="https://stocktwits.com/symbol/TRIB">TRIB</a>)&nbsp;Shares of the medical diagnostic products maker saw a staggering 15,550% jump in retail message volume after the company released “compelling” results from a study on its next-generation continuous glucose monitoring system.&nbsp;The device, designed for real-time diabetes management, demonstrated superior signal quality, accuracy, and consistency in a trial involving 30 diabetic participants.&nbsp;The system features a reusable applicator and rechargeable wearable transmitter, reducing costs by eliminating disposable components.&nbsp;Trinity said it remains on track to seek regulatory approval in the EU by 2025 and the U.S. by 2026.&nbsp;Shares fell over 13% premarket Wednesday.Silexion Therapeutics (<a href="https://stocktwits.com/symbol/SLXN">SLXN</a>)&nbsp;The cancer-focused biotech firm’s ticker saw a 9,060% surge in retail message volume as its stock more than doubled Tuesday following promising preclinical data for its tumor drug candidate SIL-204.&nbsp;The company reported that the extended-release formulation of SIL-204 reduced tumor growth by more than 50% after 30 days, with around 50% of tumors showing complete necrosis in human pancreatic models.&nbsp;Additionally, an injectable version of the drug candidate showed tumor growth inhibition in metastatic pancreatic mouse models.&nbsp;The stock continued its rally, gaining over 70% premarket Wednesday.Sharps Technology (<a href="https://stocktwits.com/symbol/STSS">STSS</a>)&nbsp;The medical packaging firm experienced a 6,233% surge in retail message volume, but for the wrong reasons.&nbsp;Shares plunged nearly 70% to a record low on Tuesday after the company announced a $20 million public offering of 14,285,714 Common Units.&nbsp;Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant, priced at $1.40 per unit, a 4.1% discount to Monday’s close.&nbsp;The company said the proceeds would be used for general corporate purposes and working capital.&nbsp;The stock continued to slide, down over 2% premarket Wednesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Current Price	$0.7143
Prev Close	$0.6976
Open	$0.69
Dividend Yield	N/A
50-Day Moving Average	$0.7088
Beta	0.62
Avg. Volume	251,417.69
PE Ratio	-0.30

52-Week High	$3.44
52-Week Low	$0.5012
Market Capitalization	$13.31M
EPS (Annual)	N/A
Price to Book	-0.24
Revenue Per Employee	N/A

TRIB
Trinity Biotech plc

Feed

News

Sentiment

Fundamentals

Info

Latest TRIB News

TRIBTrinity Biotech plc